PetVivo to Unveil Q3 2025 Financial Results in February 16 Call
PetVivo Holdings, Inc., a biomedical company specialising in animal health, will host a conference call on February 16, 2026. The session will cover its fiscal third-quarter results for the period ending December 31, 2025. Investors and analysts will have the chance to hear directly from the company's leadership. The call, led by CEO John Lai and other executives, begins at 5:00 p.m. Eastern time. After a presentation on financial performance, participants can ask questions about the company's progress. Dial-in details include a toll-free number (+1 719 359 4580), conference ID (85272254834), and passcode (737862). A live webcast will also be accessible via a link in the official news release.
PetVivo develops medical devices and treatments for companion animals, with a pipeline extending to human applications. Its flagship products include SPRYNG, which uses OsteoCushion technology, and PrecisePRP. The company has highlighted these innovations as key drivers of growth. As with any forward-looking statements, PetVivo's projections carry risks and uncertainties. Full details of these factors are available in the company's filings with the Securities and Exchange Commission.
The February 16 call will provide updates on PetVivo's financial health and product development. Shareholders and industry observers can participate by phone or webcast. The session aims to clarify the company's direction as it expands its biomedical offerings.
Read also:
- Federal Funding Supports Increase in Family Medicine Residency Program, Focusing on Rural Health Developments
- Potential Role of DHA in Shielding the Brain from Saturated Fats?
- Alternative Gentle Retinoid: Exploring Bakuchiol Salicylate for Sensitive Skin
- Hanoi initiates a trial program for rabies control, along with efforts to facilitate the transition from the dog and cat meat trade industry.
